Outlook Therapeutics has announced that its novel ophthalmic formulation, ONS-5010 (Lytenh), has received approval from the U.S. Food and Drug Administration (FDA) for the treatment of wet age-related macular degeneration (AMD). This significant milestone brings a new therapeutic option closer to patients affected by the condition, which is a leading cause of severe vision loss among older adults globally.
ONS-5010 is a proprietary formulation of bevacizumab, specifically developed for ophthalmic use. The drug works by inhibiting vascular endothelial growth factor (VEGF), a protein that plays a crucial role in the abnormal blood vessel growth characteristic of wet AMD. These fragile new vessels can leak fluid and blood, damaging the macula – the part of the retina responsible for sharp, central vision.
For UK patients, while the FDA approval is a positive indicator, the treatment would still need to undergo assessment and approval by the Medicines and Healthcare products Regulatory Agency (MHRA) and subsequently be appraised by the National Institute for Health and Care Excellence (NICE) for use within the NHS. NICE recommendations are vital for determining which treatments are cost-effective and clinically effective for widespread use in England, Wales, and Northern Ireland. Similar processes would be required in Scotland.
Wet AMD affects a significant number of individuals in the UK, with estimates suggesting over 600,000 people are living with some form of AMD. The condition typically progresses rapidly and can lead to irreversible vision loss if left untreated. Current standard treatments available on the NHS include intravitreal injections of anti-VEGF drugs such as ranibizumab (Lucentis), aflibercept (Eylea), and brolucizumab (Beovu), which aim to stabilise vision and, in some cases, improve it.
The introduction of a new anti-VEGF agent could offer clinicians and patients additional choices, potentially catering to different patient profiles or offering benefits in terms of administration or efficacy for certain subgroups. However, the exact impact on the UK healthcare landscape will depend heavily on the outcomes of the regulatory and appraisal processes, including a comparison of its cost-effectiveness and clinical benefits against existing treatments.